Rosuvastatin (20–40 mg): high intensity. Observational study performed in 253 patients with malignant pleural mesothelioma or advanced NSCLC treated with PD-1 inhibitors. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.